13F filer · CIK 1831942
Commodore Capital LP
NEW YORK, NY · filing since Q4 2020 · last filing Aug 14, 2026
Reported value
$1.7B
$-49.5M vs prior
Positions
33
New / sold out
5 / 8
Added / reduced
6 / 9
Turnover
10.7%
buys $182.8M · sells $726.0M
Top-10 weight
68.2%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | TANGO THERAPEUTICS INC | +2,250,000 | – | +$70.3M |
| New | EDITAS MEDICINE INC | +8,889,000 | – | +$28.8M |
| Added | EYEPOINT INC | +1,775,000 | +62.8% | +$25.4M |
| New | INFLARX NV | +7,300,000 | – | +$16.4M |
| Added | ASSEMBLY BIOSCIENCES INC | +415,000 | +41.5% | +$11.4M |
| Added | AVALO THERAPEUTICS INC | +535,319 | +110.8% | +$9.9M |
| Added | COGENT BIOSCIENCES INC | +161,993 | +5.6% | +$6.3M |
| Added | RELMADA THERAPEUTICS INC | +791,099 | +124.8% | +$5.5M |
| New | RESEARCH ALLIANCE CORP III | +500,000 | – | +$5.3M |
| Added | AN2 THERAPEUTICS INC | +599,967 | +25.7% | +$2.9M |
1 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | SPYRE THERAPEUTICS INC | -1,065,594 | -55.7% | $-94.6M |
| Reduced | RELAY THERAPEUTICS INC | -5,000,000 | -29.4% | $-93.5M |
| Reduced | NUVALENT INC | -733,600 | -88.0% | $-90.6M |
| Reduced | ALKERMES PLC | -1,200,000 | -28.6% | $-62.9M |
| Reduced | KYMERA THERAPEUTICS INC | -500,000 | -66.7% | $-57.3M |
| Sold out | ERASCA INC | -3,175,000 | -100.0% | $-51.4M |
| Reduced | CELLDEX THERAPEUTICS INC NEW | -1,346,616 | -49.9% | $-50.1M |
| Sold out | XENON PHARMACEUTICALS INC | -825,000 | -100.0% | $-48.0M |
| Sold out | NURIX THERAPEUTICS INC | -2,275,000 | -100.0% | $-35.3M |
| Sold out | CORVUS PHARMACEUTICALS INC | -2,258,735 | -100.0% | $-33.0M |
7 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | RELAY THERAPEUTICS INCCOM | 12,000,000 | $224.5M | 13.37% |
| 2 | ENLIVEN THERAPEUTICS INCCOM | 3,275,000 | $166.2M | 9.90% |
| 3 | ALKERMES PLCSHS | 3,000,000 | $157.2M | 9.36% |
| 4 | COGENT BIOSCIENCES INCCOM | 3,050,000 | $118.0M | 7.03% |
| 5 | AMYLYX PHARMACEUTICALS INCCOM | 5,650,000 | $101.5M | 6.04% |
| 6 | DEFINIUM THERAPEUTICS INCCOM SHS | 2,000,000 | $94.1M | 5.60% |
| 7 | SPYRE THERAPEUTICS INCCOM NEW | 846,786 | $75.2M | 4.48% |
| 8 | ALTO NEUROSCIENCE INCCOM SHS | 2,723,196 | $71.9M | 4.28% |
| 9 | TANGO THERAPEUTICS INCCOM | 2,250,000 | $70.3M | 4.19% |
| 10 | EYEPOINT INCCOM NEW | 4,600,000 | $65.8M | 3.92% |
23 more rows. Subscribe for $29/month to see every row, download the data and use the API.